AOD-9604 in Gabi — Fat Loss Peptide Research Guide
AOD-9604 research guide for Gabi. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 isn't stocked on pharmacy shelves in Gabi or anywhere else for that matter — this is a specialist compound distributed through a dedicated online market. What this means for Gabi researchers is that physical proximity is irrelevant compared to your ability to evaluate vendor quality — and those quality checks are accessible to anyone. What consistently distinguishes top AOD-9604 vendors is full COA coverage: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety screening. The sections below cover what Gabi researchers need to know about purchasing, testing, and working with AOD-9604 for scientific research use.
What Studies Say About AOD-9604
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Gabi studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Where to Buy AOD-9604 — A Researcher's Guide
The first step for any Gabi researcher sourcing AOD-9604 is locating suppliers that experienced researchers actively recommend — organic rankings are no guide to actual AOD-9604 quality. Mass spectrometry in the COA confirms that the main HPLC peak is actually AOD-9604 and not a different peptide of similar polarity — HPLC purity alone provides no identity confirmation. Warning signs in AOD-9604 vendor evaluation: prices more than 30-40% below standard market rates, no information about manufacturing source, no community presence, and COAs that lack endotoxin data. Bacteriostatic water is the standard reconstitution medium for AOD-9604 — it contains 0.9% benzyl alcohol that inhibits bacterial growth and extends reconstituted shelf life to 4 weeks when kept refrigerated.
Order AOD-9604 — ships to Gabi
COA-verified · International tracking · Research grade
AOD-9604 is supplied strictly for research applications and is not approved for human use by the FDA or equivalent agencies worldwide — all information here is educational. Storage requirements for AOD-9604: lyophilised powder at freezer temperature, reconstituted solution refrigerated at 2-8°C and finished within 30 days of reconstitution; reconstitute only with bac water. Bacterial endotoxin contamination is the primary safety concern unique to this class of compound — verify endotoxin testing is present in the lot-matched certificate before any injectable research application. Protocol documentation — documenting product details, dates, and administration precisely — is a sound practice for any AOD-9604 protocol that ensures unusual findings can be explained.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
